The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | AI-predicted NK cell fitness to guide dara & transplant strategies in newly diagnosed myeloma
Arjun Rajanna, MSc, Sylvester Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami, FL, discusses his work on using artificial intelligence (AI) to predict natural killer (NK) cell fitness to guide daratumumab (dara) and transplant strategies in newly diagnosed multiple myeloma (MM), highlighting the potential of histopathology images to provide insights into immune profiles and treatment response. He explains that his team’s model can predict CD16 expression on NK cells from routine hematoxylin and eosin (H&E)-stained bone marrow biopsy slides, opening the door to precision medicine approaches that utilize existing resources in pathology labs. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
